US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

IRWD Ironwood Pharmaceuticals Inc

4.96

0.30 (6.44%)

08 Nov 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Shares sold to cover taxes from the vesting of stock awards granted by the Issuer.

Date of Notice

05/17/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Thomas McCourt

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Haga Click aquí para más Gráficas Ironwood Pharmaceuticals.

Noticias sobre Ironwood Pharmaceuticals Inc IRWD

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 7 de Noviembre 2024 (3 días hace) • Edgar (US Regulatory)

Form 8-K - Current report
Jueves 7 de Noviembre 2024 (3 días hace) • Edgar (US Regulatory)

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
Jueves 7 de Noviembre 2024 (3 días hace) • Business Wire

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
Lunes 28 de Octubre 2024 (2 semanas hace) • Business Wire

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
Jueves 24 de Octubre 2024 (2 semanas hace) • Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Miércoles 23 de Octubre 2024 (3 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Lunes 30 de Septiembre 2024 (1 mes hace) • Edgar (US Regulatory)

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
Jueves 29 de Agosto 2024 (2 meses hace) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 14 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 14 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 9 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 8 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Ironwood Pharmaceuticals Inc Artículos de Noticias

Financial Select Sector

Euro vs US Dollar

JP Morgan Chase

BNP Paribas (QX)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones